THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE

Abstract

The prevalence of congestive heart failure (CHF) is growing further with age, and 65% of the sufferers are in the age group from 65 to 80 y.o. Despite success in CHF treatment, mean year mortality is about 6%, and mortality of those with clinically salient CHF reaches 12%. To increase duration of life it is important to prescribe efficient drug therapy, that must include beta-adrenoblockers (BAB), especially in CHF with low ejection fraction (EF) of the left ventricle (LV). Taken into account the results of SENIORS and NEMESIDA, in the year 2013 Nebivolol was included to the National Guidelines on diagnostics and treatment of CHF (IVth review). Benefits on Nebivolol are super-selectivity, vasodilation due to NO release, ability to decrease central aortal pressure, good tolerability and low risk of side effects, especially in patients with concomitant diseases. Nebivolol is effective in coronary heart disease (CHD) and arterial hypertension (AH).

Keywords

• congestive heart failure beta-adrenoblockers
• nebivolol
• national guidelines